Treats idiopathic pulmonary fibrosis (IPF). ANDA 216915, held by Sandoz. Nintedanib Esylate.
As of Nov 16, 2026, ANDA 216915 (Nintedanib Esylate), held by Sandoz, was first approved by FDA on Apr 2, 2026, with 0 approved supplements and 0 published complete response letters.
Nintedanib capsules are a kinase inhibitor indicated in adults for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2026 | Original application | Approved | None posted |
| Nintedanib EsylateEQ 100MG BASE · capsule;oral | Nintedanib Esylate | Rx |
| Nintedanib EsylateEQ 150MG BASE · capsule;oral | Nintedanib Esylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters